“It is time institutional investors took a firmer grip on buyout mania.” So wrote John Plender, a senior Financial Times writer, in a recent article to be found at http://www.ft.com/home/uk under ‘buyout mania’.
Persimmon has announced an acceleration of its Capital Return Plan, but shockingly, made no mention of the resulting acceleration of zero-cost options now estimated to be worth £500million to management. With options previously vested the total becomes £600million. The Finance Director alone will receive £72million.
If Tissue Regenix Group is to survive it will soon need more cash. Despite share price performance since listing on Nasdaq, GW Pharmaceuticals directors appear to have been overpaid.
UKSA's review of the paper is all too revealing of the fact that the intermediate shareholding model cannot be relied upon to facilitate the shareholder engagement that the government wishes to encourage.
The FRC is responsible for promoting high quality corporate governance and reporting. The UK Shareholders’ Association wants private investors to be given more opportunity to contribute to this.
The UK Shareholders’ Association (UKSA) is pleased to provide access to the latest newsletter from the International Accounting Standards Board (IASB). Read more to find the link.